Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24079499 | 0.88 | NCF1 (0.42) | CHRM5ADRA2CACHEKDM2BKCNH2 | |
| SCHEMBL21933470 | 0.86 | CHRM5 (0.36) | CHRM5ADRA2CACHEKDM2B | |
| SCHEMBL23919055 | 0.86 | CACNA2D1 (0.40) | CHRM5ADRA2CACHE | |
| SCHEMBL21933471 | 0.85 | ACHE (0.39) | CHRM5ADRA2CACHE | |
| SCHEMBL20314496 | 0.84 | ACHE (0.32) | CHRM5ADRA2CACHE | |
| SCHEMBL25133598 | 0.81 | ACHE (0.31) | CHRM5ADRA2CACHE | |
| SCHEMBL21472825 | 0.81 | ACHE (0.39) | CHRM5ADRA2CACHE | |
| SCHEMBL12092353 | 0.80 | HTR7 (0.34) | — | |
| SCHEMBL7321483 | 0.80 | CHRM5 (0.60) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL19543019 | 0.80 | HTR7 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | CHRM5 3657/4885ADRA2C 1350/4885ACHE 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.